

Priority research questions for TB/HIV in HIV-prevalent and resource-limited settings



**World Health
Organization**

TB/HIV Working Group

StopTB Partnership

Priority research questions for TB/HIV in HIV-prevalent and resource-limited settings



**World Health
Organization**

TB/HIV Working Group

Stop  Partnership

WHO Library Cataloguing-in-Publication Data

Priority research questions for tuberculosis/human immunodeficiency virus (TB/HIV) in HIV-prevalent and resource-limited settings.

WHO/HTM/TB/2010.8

WHO/HTM/HIV/2010.10

1.HIV infections. 2.Acquired immunodeficiency syndrome - prevention and control. 3.AIDS-related opportunistic infections - prevention and control. 4.Tuberculosis, Pulmonary - prevention and control. 5.Research. 6.Developing countries. I.World Health Organization.

ISBN 978 92 4 150030 2 (NLM classification: WC 503.5)

© World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Designed by Creative Lynx, Geneva, Switzerland.

Printed in France.

ACKNOWLEDGEMENTS

This document was written by Delphine Sculier, with contributions from Haileyesus Getahun, Reuben Granich, Christian Lienhardt and Matteo Zignol, on behalf of the World Health Organization (WHO) writing group from the WHO Stop TB Department and HIV/AIDS Department.

Valuable inputs were provided by an Advisory Group and a Peer Review Committee, the membership of which is given below.

Advisory Group: Jintanat Anaworanich (The HIV Netherlands Australia Thailand Research Collaboration, Thailand), Yibeltal Assefa (National HIV/AIDS Prevention and Control Office, Ethiopia), Richard Chaisson (Johns Hopkins University Center for Tuberculosis Research, the United States of America [USA]), Jeremiah Chakaya (Kenya Medical Research Institute, Kenya), Mark Cotton (Stellenbosch University, South Africa), Peter Godfrey-Faussett (London School of Hygiene and Tropical Medicine, United Kingdom [UK]), Christy Hanson (United States Agency for International Development [USAID], USA), Anthony Harries (International Union Against Tuberculosis and Lung Disease, UK), Mark Harrington (Treatment Action Group, USA), Diane Havlir (University of California San Francisco, USA), Salman Keshavjee (Harvard Medical School, USA), Michael Kimerling (Gates Foundation, USA), Steve Lawn (University of Cape Town, South Africa), Mauro Schechter (Universidade Federal Rio de Janeiro, Brazil)

Peer Review Committee: Getachew Aderaye (Addis Ababa University, Ethiopia), Connie Benson (University of California, San Diego, USA), Amy Bloom (USAID, USA), Maryline Bonnet (Médecins Sans Frontières, Switzerland), Frank Cobelens (University of Amsterdam, The Netherlands), David Cohn (University of Colorado Health Sciences Center, USA), Bob Colebunders (Institute of Tropical Medicine, Belgium), Liz Corbett (London School of Hygiene and Tropical Medicine, Malawi), Rod Escombe (Imperial College, London, UK), Jerry Friedland (Yale University, USA), Elvin Geng (University of California San Francisco, USA), Robert Gie (Stellenbosch University, South Africa), Philippe Glaziou (Stop TB Department, WHO), Eric Goemare (Médecins Sans Frontières, South Africa), Fred M. Gordin (Washington University, USA), Ernesto Jaramillo (Stop TB Department, WHO), Garry Maartens (University of Cape Town, South Africa), Dermot Maher (Medical Research Council,

Uganda), Bess Miller (Centers for Disease Control and Prevention, USA), Veronica Miller (Washington University, USA), Alwyn Mwinga (Center for Disease Control and Prevention, Zambia), Lisa Nelson (Center for Disease Control and Prevention, Mozambique), Andrew Nunn (Medical Research Council, UK), Paul Nunn (Stop TB Department, WHO), Philip Onyebujoh (Special Programme for Research and Training in Tropical Diseases, WHO), Mario Raviglione (Stop TB Department, WHO), Alasdair Reid (The Joint United Nations Programme on HIV/AIDS, Switzerland), Renee Ridzon (Gates Foundation, USA), Giorgio Roscigno (Foundation for Innovative New Diagnostics, Switzerland), Fabio Scano (WHO, China), Boniswa Seti (AIDS Rights and Alliance for Southern Africa, South Africa), Christine Sizemore (National Institute of Allergy and Infectious Diseases, USA), Soumya Swaminathan (Special Programme for Research and Training in Tropical Diseases, WHO), Robert Terry (Research Policy and Cooperation department, WHO), Annelies van Rie (University of North Carolina, USA), Jay Varma (Center for Disease Control and Prevention, China), Robin Wood (University of Cape Town, South Africa), Rony Zachariah (Médecins Sans Frontières, Belgium).

Coordinated by: Haileyesus Getahun and Delphine Sculier (Stop TB Department, WHO).

CONTENTS

ACKNOWLEDGEMENTS	iii
ABBREVIATIONS	vi
EXECUTIVE SUMMARY	1
INTRODUCTION	3
Rationale	3
Purpose	3
Target audience	4
Document preparation process	4
Prioritization of research questions	4
CHAPTER 1: TB PREVENTION	5
1.1 Preventive TB therapy	5
1.2 TB infection control	6
1.3 Antiretroviral therapy	7
1.4 TB vaccines	8
1.5 Interferon-gamma release assays	8
1.6 Priority research questions in the area of TB prevention	10
CHAPTER 2: INTENSIFIED TB CASE-FINDING	11
2.1 Clinical screening and diagnostic algorithms	11
2.2 TB Diagnostic tools	10
2.2.1 Microscopy	12
2.2.2 Culture-based methods	12
2.2.3 Gene amplification technique	12
2.2.4 Other diagnostics and point-of-care tests	13
2.3 Priority research questions in the area of intensified TB case-finding	14
CHAPTER 3: TB TREATMENT FOR PEOPLE LIVING WITH HIV	15
3.1 Antiretroviral and anti-TB therapeutic drug combinations	15
3.1.1 Rifampicin and nevirapine	15
3.1.2 Rifampicin and efavirenz	16
3.1.3 Comparison of nevirapine and efavirenz for rifampicin co-administration	16
3.1.4 Rifampicin and protease inhibitors	17
3.1.5 Triple-nucleoside reverse transcriptase inhibitor regimens	17
3.1.6 Rifabutin-based treatment regimens	17

3.2	Optimal time to start antiretroviral therapy in HIV-infected TB patients	18
3.3	Immune reconstitution inflammatory syndrome	18
3.4	TB treatment regimens	19
3.5	Priority research questions in the area of TB treatment for people living with HIV	20
CHAPTER 4:	DRUG RESISTANT TB AND HIV	21
4.1	Epidemiology of HIV infection and drug-resistant TB	21
4.2	Diagnostic issues in the identification of drug resistant TB in people living with HIV	22
4.3	MDR-TB treatment strategies in people living with HIV	22
4.4	Management of contacts of drug-resistant TB patients	23
4.5	Priority research questions on drug-resistant TB and HIV infection	24
CHAPTER 5:	CHILDHOOD AND MATERNAL TB AND HIV	25
5.1	Paediatric TB and HIV	25
5.1.1	Epidemiology of TB in children living with HIV	25
5.1.2	TB prevention in children living with HIV	25
5.1.3	TB diagnosis in children living with HIV	26
5.1.4	TB treatment in children living with HIV	26
5.1.5	Drug-resistant TB in children living with HIV	27
5.2	Maternal TB and HIV coinfection and mother-to-child transmission	27
5.3	Priority research questions in maternal and childhood TB and HIV coinfection	29
CHAPTER 6:	INTEGRATED TB AND HIV SERVICES	30
6.1	TB and HIV service delivery	30
6.2	Community-level interventions	32
6.3	HIV-associated TB in special populations	33
6.4	Priority research questions in TB and HIV services integration	34
REFERENCES		35
ANNEX 1		52
ANNEX 2		54

ABBREVIATIONS

aHR	adjusted hazard ratio
AIDS	acquired immunodeficiency syndrome
aOR	adjusted odds ratio
BCG	bacille Calmette-Guérin
CI	confidence interval
CYP	cytochrome P450
DNA	deoxyribonucleic acid
ELISPOT	enzyme-linked immunosorbent spot
HIV	human immunodeficiency virus
HR	hazard ratio
IGRA	interferon-gamma release assay
IRIS	immune reconstitution inflammatory syndrome
MDR	multidrug resistant
MODS	microscopic-observation drug susceptibility
OR	odds ratio
P	p-value
PCR	polymerase chain reaction
RCT	randomized controlled trial
RNA	ribonucleic acid
RR	relative risk
TB	tuberculosis
TDR	UNDP/UNICEF/World Bank/WHO Special Programme for Research and Training in Tropical Diseases
UNAIDS	Joint United Nations Programme on HIV/AIDS
UNDP	United Nations Development Programme
UNICEF	United Nations Children's Fund

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29047

